|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:blackBoxWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:eliminationHalfLife
|
5-9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMVFI-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPatentExpiry
|
2024 (US)
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
9N1LH5MYA2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06690
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
gptkb:Factor_Xa_inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2J2, CYP-independent)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:DB06690
gptkb:CHEMBL2010604
8056452
9875401
D08917
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
rash
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of venous thromboembolism
|
|
gptkbp:bfsParent
|
gptkb:Laughing_Gas
|
|
gptkbp:bfsLayer
|
6
|